Terms: = Prostate cancer AND BCL2, Bcl-2, 596, ENSG00000171791 AND Staging
12 results:
1. Confirmation of PSMA expression measured on [68Ga]Ga-PSMA PET/CT by immunohistochemistry in prostate adenocarcinoma.
Sengoz T; Sen Turk N; Ozlulerden Y; Celen S; Gultekin A; Yaylali O; Yuksel D
Nucl Med Rev Cent East Eur; 2023; 26(0):68-73. PubMed ID: 37381796
[TBL] [Abstract] [Full Text] [Related]
2. Artificial intelligence is a promising prospect for the detection of prostate cancer extracapsular extension with mpMRI: a two-center comparative study.
Hou Y; Zhang YH; Bao J; Bao ML; Yang G; Shi HB; Song Y; Zhang YD
Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):3805-3816. PubMed ID: 34018011
[TBL] [Abstract] [Full Text] [Related]
3. Apoptotic and predictive factors by Bax, Caspases 3/9, bcl-2, p53 and Ki-67 in prostate cancer after 12 Gy single-dose.
Pisani C; Ramella M; Boldorini R; Loi G; Billia M; Boccafoschi F; Volpe A; Krengli M
Sci Rep; 2020 Apr; 10(1):7050. PubMed ID: 32341393
[TBL] [Abstract] [Full Text] [Related]
4. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
[TBL] [Abstract] [Full Text] [Related]
5. Immunohistochemical expression of bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy.
Revelos K; Petraki C; Gregorakis A; Scorilas A; Papanastasiou P; Koutsilieris M
Anticancer Res; 2005; 25(4):3123-33. PubMed ID: 16080576
[TBL] [Abstract] [Full Text] [Related]
6. Prostatic ductal adenocarcinoma showing bcl-2 expression.
Tulunay O; Orhan D; Baltaci S; Gögüş C; Müftüoglu YZ
Int J Urol; 2004 Sep; 11(9):805-8. PubMed ID: 15379952
[TBL] [Abstract] [Full Text] [Related]
7. Molecular markers in prostate cancer: the role in preoperative staging.
Moul JW; Merseburger AS; Srivastava S
Clin Prostate Cancer; 2002 Jun; 1(1):42-50. PubMed ID: 15046712
[TBL] [Abstract] [Full Text] [Related]
8. The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy.
Moul JW; Kane CJ; Malkowicz SB
Urol Clin North Am; 2001 Aug; 28(3):459-72. PubMed ID: 11590806
[TBL] [Abstract] [Full Text] [Related]
9. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients.
Lee N; Fawaaz R; Olsson CA; Benson MC; Petrylak DP; Schiff PB; Bagiella E; Singh A; Ennis RD
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1443-6. PubMed ID: 11121646
[TBL] [Abstract] [Full Text] [Related]
10. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy.
Wu TT; Wang JS; Lu CM; Lee YH; Huang JK
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923
[TBL] [Abstract] [Full Text] [Related]
11. [Histopathological effect and its predictors of neoadjuvant hormonal therapy by combined androgen blockade].
Ito T; Mamiya Y; Aizawa T; Akiyama A; Yamamoto S; Tsuzuki M; Yoshimasa O; Miki M; Furusato M
Nihon Hinyokika Gakkai Zasshi; 1999 Sep; 90(9):779-83. PubMed ID: 10517086
[TBL] [Abstract] [Full Text] [Related]
12. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
Moul JW
Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
[TBL] [Abstract] [Full Text] [Related]
